Introduction: During restoration of hypoplastic maxillary edentulous alveolar bone, the use of bone graft materials have gain importance for improving bone formation and healing, resulting in better osseous support for dental implants, especially after maxillary sinus graft. The use of autogenous bone graft is limited due to its resulting complications, creation of an additional bone defect and paresthesia of donor site. Due to the lack of osteogenetic properties of allogenic bone, xenograft, and alloplast, a longer period of time is required for the healing process to be completed. This prospective study was designed to qualify the safety and efficacy of Bongros-BMP (Bioalpha, Korea), incorporating the osteoinductive ErhBMP-2 (recombinant human bone morphogenic protein) in the osteoconductive hydroxyapatite as a single bone graft material, comparing with bovine xenograft (Bio-Oss ^® , Geistlich Pharma Ag, Switzerland).

Method: Strict inclusion criteria was used for this study, regarding patient’s age (40–70 years old), edentulous site (posterior maxilla), alveolar ridge height (2–6 mm), alveolar bone width (>6 mm), and patient’s medical condition (absence of maxillary sinusitis and bone metabolic disease). During maxillary sinus graft, Bongros-BMP or Bio-Oss, as bone graft materials, was selected and applied randomly in 15 patients. Bone healing was assessed 3 months after the first implant surgery by computerized tomography and bone biopsy.

Results: Good bone healing process and implant osteointegration was observed in all patients. Complications, such as maxillary sinusitis and wound dehiscence, were noticed in one case of the Bongros-BMP group, respectively.

Conflict of interest: None declared.